Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer

Lung Cancer

Volumn 68, Issue 3, 2010, Pages 409-414

  Takiguchi, Yuichi ^a   Tada, Yuji ^a   Gemma, Akihiko ^b   Kudoh, Shoji ^b   Hino, Mitsunori ^c   Yoshimori, Kozo ^d   Yoshimura, Akinobu ^b,e   Nagao, Keiichi ^e   Niitani, Hisanobu ^e  

^a CHIBA UNIVERSITY   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^d Japan Anti Tuberculosis Association   (Japan)

^e Tokyo Cooperative Oncology Group   (Japan)

Author keywords

Docetaxel; Non small cell lung cancer; Phase I study; Phase II study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROPYRIMIDINE DERIVATIVE; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; VINDESINE; DRUG COMBINATION; OTERACIL; S 1 (COMBINATION); TAXOID; TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BRAIN INFARCTION; CANCER PATIENT; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HYPOCALCEMIA; HYPOHEMOGLOBINEMIA; HYPONATREMIA; HYPOXIA; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN DEFECT; STOMACH PERFORATION; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; DOSE CALCULATION; DRUG COMBINATION; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL;

ADMINISTRATION, ORAL; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG COMBINATIONS; DRUG DOSAGE CALCULATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; OXONIC ACID; SURVIVAL ANALYSIS; TAXOIDS; TEGAFUR;

EID: 77952545961     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.08.009     Document Type: Article

References (28)

1. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
2. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
3. Kubota K., Watanabe K., Kunitoh H., Noda K., Ichinose Y., Katakami N., et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: The Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004, 22:254-261.
4. Ohe Y., Ohashi Y., Kubota K., Tamura T., Nakagawa K., Negoro S., et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007, 18:317-323.
5. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
6. Pirker R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., Park K., et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008, 26(Suppl.). [abstract 3].
7. D'Addario G., Pintilie M., Leighl N.B., Feld R., Cerny T., Shepherd F.A. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A meta-analysis of the published literature. J Clin Oncol 2005, 23:2926-2936.
8. Shirasaka T., Shimamato Y., Ohshimo H., Yamaguchi M., Kato T., Yonekura K., et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs 1996, 7:548-557.
9. Giller S.A., Zhuk R.A., Lidak M. [Analogs of pyrimidine nucleosides. I. N1-(alpha-furanidyl) derivatives of natural pyrimidine bases and their antimetabolities]. Doklady Akademii Nauk SSSR 1967, 176:332-335.
10. Shirasaka T., Shimamoto Y., Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993, 53:4004-4009.
11. Tatsumi K., Fukushima M., Shirasaka T., Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 1987, 78:748-755.
12. Koizumi W., Tanabe S., Saigenji K., Ohtsu A., Boku N., Nagashima F., et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003, 89:2207-2212.
13. Ajani J.A., Lee F.C., Singh D.A., Haller D.G., Lenz H.J., Benson A.B., et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006, 24:663-667.
14. Inokuchi M., Yamashita T., Yamada H., Kojima K., Ichikawa W., Nihei Z., et al. Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer 2006, 94:1130-1135.
15. Yamaguchi K., Shimamura T., Hyodo I., Koizumi W., Doi T., Narahara H., et al. Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 2006, 94:1803-1808.
16. Kawahara M., Furuse K., Segawa Y., Yoshimori K., Matsui K., Kudoh S., et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001, 85:939-943.
17. Takahashi I., Emi Y., Kakeji Y., Uchida J., Fukushima M., Maehara Y. Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts. Oncology 2005, 68:130-137.
18. Kodera Y., Fujiwara M., Yokoyama H., Ohashi N., Miura S., Ito Y., et al. Combination of oral fluoropyrimidine and docetaxel: reappraisal of synergistic effect against gastric carcinoma xenografts. In Vivo 2005, 19:861-866.
19. Wada Y., Yoshida K., Suzuki T., Mizuiri H., Konishi K., Ukon K., et al. Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer 2006, 119:783-791.
20. Ichikawa W., Uetake H., Shirota Y., Yamada H., Nishi N., Nihei Z., et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003, 9:786-791.
21. Ichikawa W., Uetake H., Shirota Y., Yamada H., Takahashi T., Nihei Z., et al. Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 2003, 89:1486-1492.
22. Yoshida K., Hirabayashi N., Takiyama W., Ninomiya M., Takakura N., Sakamoto J., et al. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res 2004, 24:1843-1851.
23. Atagi S., Kawahara M., Kusunoki Y., Takada M., Kawaguchi T., Okishio K., et al. Phase I/II study of docetaxel and S-1 in patients with previously treated non-small cell lung cancer. J Thorac Oncol 2008, 3:1012-1017.
24. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
25. Koo L.C., Clark J.A., Quesenberry C.P., Higenbottam T., Nyberg F., Wolf M.K., et al. National differences in reporting 'pneumonia' and 'pneumonia interstitial': an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions. Pharmacoepidemiol Drug Saf 2005, 14:775-787.
26. Katakami N., Takiguchi Y., Yoshimori K., Isobe H., Bessho A., Yoshimura A., et al. Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group. J Thorac Oncol 2006, 1:447-453.
27. Hotta K., Kiura K., Tabata M., Harita S., Gemba K., Yonei T., et al. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 2005, 11:417-424.
28. Ando M., Okamoto I., Yamamoto N., Takeda K., Tamura K., Seto T., et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006, 24:2549-2556.